Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
Objectives: Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis, the only approved and reimbursed pharmacotherapy for non-HSCT candidates in Belgium is ruxolitinib. Methods: These updated recommendations are based on a consensus reached during two meetings and provide guidance for ruxolitinib administration in myelofibrosis patients considering the particularities of Belgian reimbursement criteria. Results and D... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Schlagwörter: | Sciences bio-médicales et agricoles / anemia / Belgium / myelofibrosis / reimbursement / Ruxolitinib / splenomegaly / symptom burden / transplantation |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26589031 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/339124 |